JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders

@article{Vainchenker2018JAKIF,
  title={JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders},
  author={William Vainchenker and Emilie Leroy and Laure Gilles and Caroline Marty and Isabelle Plo and S N Constantinescu},
  journal={F1000Research},
  year={2018},
  volume={7}
}
JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as the driver mutation of the majority of non- BCR-ABL1 myeloproliferative neoplasms (MPNs). Subsequently, the search for JAK2 inhibitors continued with the discovery that the other driver mutations ( CALR and MPL) also exhibited persistent JAK2 activation. Several type I ATP-competitive JAK inhibitors with different specificities were assessed in clinical trials and exhibited minimal hematologic toxicity… 

Figures and Tables from this paper

Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms
TLDR
Concomitant improvement of insight into MPN biology is needed to inform tailored therapeutic strategies for individual MPN patients, and special focus should be placed on myelofibrosis patients with anemia and thrombocytopenia, a delicate patient population at high need for options.
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives
TLDR
The role of JAKi in the modern management of patients with MPN is critically discussed, with almost 50% lose response by three years and dose-dependent toxicities may lead to suboptimal dosing or treatment discontinuation.
Management of myelofibrosis after ruxolitinib failure
TLDR
Strategies to ameliorate ruxolitinib resistance or intolerance, and outcomes of clinical trials in patients with myelofibrosis receiving second-line JAK inhibitors after ruxolinib treatment are reviewed.
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
TLDR
The recently developed pan-PIM inhibitor INCB053914 augments the efficacy of the US Food and Drug Administration-approved JAK1/2 inhibitor ruxolitinib in both in vitro and in vivo MPN models, and these findings support the notion that INCB53914, which is currently in clinical trials in patients with advanced hematologic malignancies, in combination with ruxolitanib may be effective in MPN patients.
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
TLDR
The preclinical basis and existing clinical data for JAK inhibitor combination strategies are reviewed while highlighting emerging strategies of particular interest.
Chronic Myeloproliferative Neoplasms: Some Remaining Challenges
TLDR
Imatinib substantially and durably reduces the number of CML cells in the CP at a daily oral dose of 400mg, and the life expectancy of most patients now approaches that of the general population.
Rapid development of multiple nonmelanoma skin cancers secondary to ruxolitinib: a case report
TLDR
A 69-year-old male with prostate cancer being treated with ruxolitinib who developed multiple nonmelanoma skin cancers over a 13-month period is reported.
Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms
TLDR
Molecular mechanisms at the basis of disease persistence and new therapeutic attempts to overcome them are discussed in the review and unexpected connections among signal transduction pathways highlighted in neoplastic cells suggest new strategies to overcome neoplastics cell adaptation.
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
TLDR
The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB, and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously Jaki-treated patients.
Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms
TLDR
Specific metabolic changes associated with epigenetic deregulation may identify patient populations that exhibit specific metabolic vulnerabilities that are absent in normal hematopoietic cells, and thus provide a potential basis for the development of more effective personalized therapeutic approaches.
...
...

References

SHOWING 1-10 OF 228 REFERENCES
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
TLDR
Ruxolitinib is in late-phase clinical trials in essential thrombocythemia, in which it could fill an important void for patients with troublesome symptoms, and less myelosuppressive JAK2 inhibitors such as pacritinib or NS-018 could prove to be very useful additions to the therapeutic armamentarium in MF.
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths.
TLDR
The risk-benefit balance favors use of currently available JAK inhibitors in only a select group of patients with myelofibrosis, and their potential value in polycythemia vera is undermined by the absence of evidence for a disease-modifying effect and presence of arguably superior alternatives.
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
JAK2 kinase inhibitors were developed for the treatment of myeloproliferative neoplasms (MPNs), following the discovery of activating JAK2 mutations in the majority of patients with MPN. However, to
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors
TLDR
The data support the use of a combination of JAK2 and pan‐class I PI3K inhibitors in the treatment of MPNs and show strong inhibitory effects on erythropoietin‐independent erythroid colonies from MPN patients and JAK 2 V617F knock‐in mice.
HSP 90 is a therapeutic target in JAK 2-dependent myeloproliferative neoplasms in mice and humans
JAK2 kinase inhibitors were developed for the treatment of myeloproliferative neoplasms (MPNs), following the discovery of activating JAK2 mutations in the majority of patients with MPN. However, to
Novel myelofibrosis treatment strategies: potential partners for combination therapies
TLDR
Investigation of JAK inhibitor resistance and broad contributions to MF disease pathogenesis from epigenetic deregulators, pathways that work in concert with JAK/STAT, fibrosis-promoting factors and the MF megakaryocyte suggest that numerous options may be partnered with a JAK inhibitors.
Managing side effects of JAK inhibitors for myelofibrosis in clinical practice
TLDR
This review focuses on the management of both common and uncommon side effects arising from the use of currently approved and clinical trial JAKi, most of the discussion concerns ruxolitinib although both pacritinib and momelotinib which have been in recent large, multinational phase III trials.
Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.
  • A. Tefferi
  • Medicine, Biology
    The New England journal of medicine
  • 2012
TLDR
This work has confirmed the presence of a gain-of-function mutation in the gene encoding Janus kinase (JAK) 2 that is relevant to JAK–signal transducer and activator of transcription (STAT) in patients with JAK2 V617F–negative disease.
Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy
TLDR
It is shown that JAK2 inhibitor persistence is associated with reactivation of JAK–STAT signalling and with heterodimerization between activatedJAK2 and JAK1 or TYK2, consistent with activation of Jak2 in trans by other JAK kinases.
...
...